New Clinical Trials
laurabbook@gmail.com2019-11-08T08:36:04-08:00*November 2019* Phase II progression on any TKI with a new 3rd generation TKI, lazertinib. Location: Montefiore/Einstein in NYC. More
8 November 2019
8 November 2019
New Data Challenge Current Standard in Treating EGFR+ Lung Cancer
laurabbook@gmail.com2019-11-08T08:20:15-08:00*September 2019* by Dr. Mark Kris for Medscape This is Mark Kris from Memorial Sloan Kettering. Just when we thought
8 November 2019
Analyzing Best Practices for Targeting EGFR Resistance Mutations in EGFR+ NSCLC
laurabbook@gmail.com2019-11-08T08:12:57-08:00*June 2019* by Nichole Tucker for Targeted Oncology Tyrosine kinase inhibitors (TKIs) targeting the epidermal growth factor receptor (EGFR) have
8 November 2019
Overcoming Targeted Therapy Resistance in NSCLC
laurabbook@gmail.com2019-11-08T08:04:07-08:00*October 2019* by Caroline Seymour for OncLive Insight into the natural history of EGFR-, ALK-, and ROS1-positive non–small cell lung
25 September 2019
CAR-T Tx Shifts into First Gear in Lung Cancer
laurabbook@gmail.com2019-09-25T15:24:37-07:00*October 2018* by Shalmali Pal Medpage Today and ASCO Chimeric antigen receptor (CAR) T-cell therapy took a victory lap in early
25 September 2019
Hypofractionated EGFR tyrosine kinase inhibitor limits tumor relapse through triggering innate and adaptive immunity
laurabbook@gmail.com2019-09-25T15:17:16-07:00*August 2019* Science Immunology Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are a first-line therapy for rapidly killing
25 September 2019
How Patients Can Participate in EGFR Research (Video)
laurabbook@gmail.com2019-09-25T14:44:17-07:00*August 2019* Dr. Pasi Janne How Patients can Participate in EGFR Research: A conversation and Q&A with Dr. Pasi Janne,
12 August 2019
In Depth Overview of Tyrosine Kinase Inhibitor Treatment of EGFR+ Lung Cancer
laurabbook@gmail.com2019-08-12T16:38:39-07:00*July 2019* by Dr. C.H. Weaver M.D. for CancerConnect. Tagrissio, Tarceva and other TKI therapy for EGFR + NSCLC continue to evolve and
12 August 2019
Are BiTE Antibodies The Next Treatment for EGFR + NSCLC?
laurabbook@gmail.com2019-08-12T16:21:40-07:00*July 2019* by Dr. C.H. Weaver M.D. for CancerConnect. BiTE antibodies are showing promise as a potential new treatment option for those
12 August 2019
Cumulative Antibiotic Use Significantly Decreases Efficacy of Checkpoint Inhibitors in Patients with Advanced Cancer
laurabbook@gmail.com2019-08-12T16:26:24-07:00*July 2019* The Oncologist. With the advent of immunotherapy, substantial progress has been made in improving outcomes for patients with